Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia
Conditions
Interventions
MCI-196
Placebo
Locations
39
United States
Glendale, Arizona, United States
Tempe, Arizona, United States
Hot Springs, Arkansas, United States
Paragould, Arkansas, United States
Pine Bluff, Arkansas, United States
Fountain Valley, California, United States
Start Date
September 1, 2007
Primary Completion Date
September 1, 2009
Completion Date
September 1, 2009
Last Updated
January 8, 2026
NCT07547098
NCT06446739
NCT07232537
NCT06278207
NCT07493642
NCT07241390
Lead Sponsor
Tanabe Pharma Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions